TEODORO BORDADOR: Open Payments
NPI 1750358313 · SALEM, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,903 in 217 payments from 14 companies in 2025. Trend: 2023 $4,401 · 2024 $5,835 · 2025 $4,903
Food & beverage: $4,903
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $844 |
| ABBVIE INC. | 35 | $637 |
| E.R. Squibb & Sons, L.L.C. | 14 | $564 |
| Neurocrine BioSciences, Inc. | 41 | $532 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $448 |
| Supernus Pharmaceuticals, Inc. | 16 | $415 |
| Otsuka America Pharmaceutical, Inc. | 23 | $338 |
| Axsome Therapeutics, Inc. | 8 | $326 |
| Alkermes, Inc. | 14 | $301 |
| Vanda Pharmaceuticals Inc. | 8 | $255 |
Products named: VRAYLAR, COBENFY, INGREZZA, CAPLYTA, AUSTEDO XR, UZEDY, Qelbree, Auvelity.
Industry payments across IN — which companies pay providers there.
